A Multicenter, Adaptive, Randomized, Double-blinded, Placebo-controlled Phase II/III Trial to Evaluate the Efficacy and Safety of Monoclonal Antibody SCTA01 Against SARS-CoV-2 in Hospitalized Patients With Severe COVID-19
Latest Information Update: 05 Apr 2023
At a glance
- Drugs Upanovimab (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Sponsors Sinocelltech
- 07 Apr 2021 Planned End Date changed from 10 Oct 2021 to 27 Dec 2021.
- 07 Apr 2021 Planned primary completion date changed from 10 May 2021 to 27 Jun 2021.
- 07 Apr 2021 Status changed from not yet recruiting to recruiting.